Meihua International Medical's subsidiary will bring 12 new products to the 87th China International Medical Equipment Fair

PR Newswire ·  05/15/2023 19:30

Yangzhou, China2023/5/15 /PRNewswire/ -- Meihua International Medical Technology Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA), a reputable Class I, Class II and Class III disposable medical device manufacturer and supplier with operating subsidiaries in China, announced today that its wholly-owned subsidiary Jiangsu Huadong Medical Devices Co., Ltd. (“Jiangsu Huadong”) will be invited to participate in China's largest and most prestigious medical industry exhibition -- the 87th China International Medical Equipment Fair (“CMEF”) for the 12th time in a row. The exhibition will be held in Shanghai from May 14 to 17, 2023, providing an excellent platform for East Jiangsu to showcase its cutting-edge medical devices and technology.

Jiangsu Huadong will present a total of 35 medical devices at the exhibition, including 12 new products. These products will have a significant impact on the industry, including surgical respiratory oxygen production equipment, orthopedic fixed traction equipment, and intense pulsed light therapy equipment. The product has also obtained China's Class I and Class II medical device certifications, as well as national 3C certifications comparable to other product quality and safety standardization certifications (such as the European CE system). These medical devices are widely used in the market and are suitable for professional hospital treatment scenarios and personal family health and aesthetic fields.Jiangsu Huadong's booth is located in Hall 5.2 in Hall 5.

The CMEF is held once every year in spring and fall, and has been held for over 40 years. CMEF provides a platform for medical device manufacturers, suppliers and distributors from around the world to showcase their latest products, technology and services. CMEF covers a wide range of medical equipment and related products, including diagnostic imaging, in vitro diagnostics, surgical instruments and medical consumables, hospital construction and information technology. The exhibition also attracted a large number of visitors from China and the world from the medical industry, including hospital administrators, doctors, nurses, and medical device dealers and distributors.

Mr. Liu Yongjun, Chairman of Mayfair International, commented, “Participating in this exhibition is a key milestone in the expansion of Meihua International's influence in the Chinese and European markets. We believe this exhibition will provide East China, Jiangsu with an excellent opportunity to connect with potential customers, partners and investors while showcasing the quality and innovation of our products.”

“We are confident that participating in CMEF will help achieve our post-pandemic strategic goals and help us continue to advance our goal of becoming a leader in the global medical device industry.”

About Meihua International Medical Technology Co., Ltd.

Meihua International Medical Technologies Co., Ltd. (Meihua International Medical Technologies Co., Ltd.) It is a well-known manufacturer and supplier of Class I, Class II and Class III disposable medical devices in China, with operating subsidiaries in China. The company manufactures and sells Class I disposable medical consumables such as eye drop bottles, medicine bottles, artificial anal bags, etc., as well as Class II and Class III disposable medical devices such as identification wristbands, gynecological examination kits, surgical kits, medical brushes, medical dressings, masks, disposable infusion pumps, electronic pumps, puncture packs, etc., and distributes disposable medical devices purchased from other manufacturers as agents. The company has passed international “CE” certification and ISO 13485 system certification, and has registered more than 20 products with the US FDA (registration number: 3006554788). The company has been serving hospitals, pharmacies, medical institutions and medical equipment companies for over 30 years. More than 800 products have been sold domestically, and more than 120 products have been exported to more than 30 countries, covering Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit:.

Forward-looking statements

The statements in this press release relating to the Company's future expectations, plans, and prospects constitute forward-looking statements as defined by the Private Securities Liability Reform Act of 1995. Forward-looking statements include statements about plans, goals, objectives, strategies, future events, expected performance, assumptions, and any other factual statement that has not occurred. Any written statement involving “may”, “will”, “want”, “should”, “believe”, “expect”, “anticipate”, “estimate”, or similar unfactual language, in particular regarding the company's listing on the NASDAQ global market and completion of that offering, should be considered a forward-looking statement. Due to various factors, actual results may differ materially from historical results or those expressed in these forward-looking statements. These factors include but are not limited to the company's strategic goals, the company's future plans, market demand and user acceptance of the company's products or services, technological updates, economic trends, the reputation and brand of the enterprise, the impact of industry competition and bidding, relevant policies and regulations, the ups and downs of China's macroeconomic conditions, the international market conditions of the company's services, and related risks and related assumptions disclosed in the prospectus. In view of the above and other related reasons, we recommend that investors do not blindly rely on such forward-looking statements, and we urge investors to check the company's relevant documents on the SEC website to obtain other factors that may influence the company's future operating results. The Company is not obligated to publicly revise these forward-looking statements due to changes in these forward-looking statements due to specific events or reasons after the filing of these documents.

Janice Wang
Weiss Investor Relations Services, Inc.
Telephone: +86 13811768599

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment